DaVita (NYSE:DVA) and Fresenius Medical Care (NYSE:FMS) are down 4% and 3%, respectively, premarket, both on light volume, in apparent response to the commencement of a clinical trial evaluating a home dialysis device from CVS Health (NYSE:CVS) that could pose a competitive threat.
The HemoCare device was designed by DEKA REsearch & Development Corp., a firm headed by Segway inventor Dean Kamen. CVS owns exclusive U.S. rights to the product.
Update: CVS says the trial will enroll up to 70 patients across as many as 10 U.S. sites.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.